Bill > A00265

This bill modifies existing New York state law to expand the availability and definition of opioid reversal agents, which are medications like naloxone that can counteract the effects of an opioid overdose. The bill requires the Department of Health to make available any formulation and dosage of opioid reversal agents that have been approved by the Federal Food and Drug Administration (FDA), moving away from previous limitations that restricted options primarily to naloxone. The legislation mandates that the state maintain a publicly accessible online directory of opioid reversal agent distributors, including detailed information such as addresses, contact details, services offered, insurance accepted, and hours of operation. Additionally, the bill stipulates that the state will fully cover the cost of FDA-approved nasal naloxone products, with any additional costs for alternative products being the responsibility of the purchaser. This approach aims to increase access to life-saving overdose reversal medications and provide more comprehensive information to the public about where these critical resources can be obtained, ultimately supporting efforts to combat the opioid crisis.

Budget and Finance, Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A265